Spring Creek Capital’s ZyVersa Therapeutics, Inc. Warrants ZVSAW Stock Holding History

Spring Creek Capital’s Portfolio ZVSAW Stock Details ZVSAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-262,500	Closed	-$45K	–	624
2022 Q1	$45K	Buy	+262,500	New	+$53.2K	﹤0.01%	583

Other funds holding ZVSAW

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

Hudson Bay Capital Management

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Spring Creek Capital's ZVSAW Position: Q2 2022 in Review

Spring Creek Capital sold out of ZyVersa Therapeutics, Inc. Warrants (ZVSAW) in Q2 2022, closing a stake of 262,500 shares — an estimated $45K sold.

Spring Creek Capital first reported a position in ZVSAW in Q1 2022 and held it in 1 quarter. The position peaked at $45K in Q1 2022. 16 funds tracked by Wall St. Rank hold ZVSAW as of Q2 2022.

Spring Creek Capital reported no remaining ZyVersa Therapeutics, Inc. Warrants position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 262,500 ZyVersa Therapeutics, Inc. Warrants shares in Q2 2022, an estimated $45K.
Spring Creek Capital first reported a position in ZyVersa Therapeutics, Inc. Warrants in Q1 2022 and held it in 1 quarter.
Spring Creek Capital's ZyVersa Therapeutics, Inc. Warrants position peaked at $45K in Q1 2022.
16 funds tracked by Wall St. Rank held ZyVersa Therapeutics, Inc. Warrants as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.